In recent years, immune checkpoint (e.g., programmed cell death protein 1 (PD-1)/ programmed cell death-ligand protein 1 (PD-L1)) blockade (ICB) therapy has emerged as a promising therapeutic strategy against cancer [1–3]. The gene discussed is PDCD1; the disease is cancer.